FibroGen (FGEN) Getting Somewhat Positive Press Coverage, Analysis Shows

News headlines about FibroGen (NASDAQ:FGEN) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. FibroGen earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 43.8351862686183 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of FibroGen (NASDAQ:FGEN) traded up $0.55 during trading on Friday, reaching $49.50. 337,707 shares of the company’s stock traded hands, compared to its average volume of 523,167. The stock has a market capitalization of $4,023.57, a price-to-earnings ratio of -24.26 and a beta of 1.55. FibroGen has a one year low of $21.05 and a one year high of $60.15. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83.

FGEN has been the topic of several analyst reports. Mizuho initiated coverage on shares of FibroGen in a report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 target price on the stock. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub cut shares of FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $65.67.

In other FibroGen news, CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $54.83, for a total value of $1,036,287.00. Following the transaction, the chief executive officer now directly owns 3,176,861 shares in the company, valued at $174,187,288.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $42.80, for a total transaction of $85,600.00. Following the completion of the transaction, the director now owns 22,000 shares in the company, valued at $941,600. The disclosure for this sale can be found here. Insiders sold 329,982 shares of company stock worth $16,234,608 over the last quarter. 13.60% of the stock is currently owned by insiders.

WARNING: “FibroGen (FGEN) Getting Somewhat Positive Press Coverage, Analysis Shows” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.themarketsdaily.com/2018/01/14/fibrogen-fgen-getting-somewhat-positive-press-coverage-analysis-shows.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply